Profile and variables related to antipsychotic consumption according to dementia subtypes

International Psychogeriatrics

Volumn 24, Issue 6, 2012, Pages 940-947

  Calvó Perxas, Laia ^a   De Eugenio, Rosa María ^b   Marquez Daniel, Fabian ^c   Martínez, Raül ^d   Serena, Joaquín ^e   Turbau, Josefa ^f   Vilalta Franch, Joan ^a,g   Viñas, Marta ^h   Turró Garriga, Oriol ^a   Roig, Anna Maria ⁱ   López Pousa, Secundino ^a,g   Garre Olmo, Josep ^a,j  

^a Hospital de Santa Caterina   (Spain)

^b Hospital de Palamos   (Spain)

^c Hospital d'Olot   (Spain)

^d HOSPITAL DE FIGUERES   (Spain)

^e HOSPITAL JOSEP TRUETA   (Spain)

^f Hospital de Campdevanol   (Spain)

^g Hospital de Santa Caterina   (Spain)

^h Hospital de Blanes   (Spain)

ⁱ Pharmacy Unit   (Spain)

^j UNIVERSITY OF GIRONA   (Spain)

more..

Author keywords

antipsychotics; behavioral and psychological symptoms of dementia (BPSD); dementia; dementia with Lewy bodies (DLB); epidemiology

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CHLORPROMAZINE; CLOTIAPINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DISEASE SEVERITY; DRUG USE; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; OUTCOME ASSESSMENT; PARKINSONISM;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; CROSS-SECTIONAL STUDIES; DEMENTIA; DEMENTIA, VASCULAR; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMANS; LEWY BODY DISEASE; LOGISTIC MODELS; MALE; PHYSICIAN'S PRACTICE PATTERNS; REGISTRIES; SPAIN;

EID: 84860186163     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610212000026     Document Type: Article

References (31)

1. American Psychiatric Association. (1994). Diagnostic and Statistical Manual of Mental Disorders DSM-IV. Washington, DC: American Psychiatric Association.
2. Ballard, C. et al. (2002). Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. International Journal of Geriatric Psychiatry, 17, 140-145. doi:10.1002/gps.543. (Pubitemid 34130304)
3. Blessed, G., Tomilson, B. E. and Roth, M. (1968). The association between quantitative measures of dementia, and of senile change in the cerebral grey matter of elderly subjects. British Journal of Psychiatry, 114, 797-811.
4. Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.
5. Fort, I., Formiga, F., Robles, M. J., Regalado, P., Rodríguez, P. and Barranco, E. (2010). Alta prevalencia de consumo de neurolépticos en las personas ancianas con demencia. Medicina Clinica, 134, 101-106.
6. Garre-Olmo, J., López-Pousa, S., Monserrat-Vila, S., Pericot-Nierga, I., Turon-Estrada, A. and Lax-Pericall, C. (2007). Viabilidad de un registro de demencias: características clínicas y cobertura diagnóstica. Revista de Neurología, 44, 385-391. (Pubitemid 350292691)
7. Garre-Olmo, J. et al. (2009). A clinical registry of dementia based on the principle of epidemiological surveillance. BMC Neurology, 9, 5. doi:10.1186/1471-2377-9-5.
8. Garre-Olmo, J. et al. (2010a). Incidence and subtypes of early-onset dementia in a geographically defined general population. Neurology, 75, 1249-1255. doi:10.1212/WNL.0b013e3181f5d4c4.
9. Garre-Olmo, J., López-Pousa, S. and Vilalta-Franch, J. (2010b). Grouping and trajectories of the neuropsychiatric symptoms in patients with Alzheimer's disease, Part I: symptom clusters. Journal of Alzheimer's Disease, 22, 1157-1167. doi:10.3233/JAD-2010-101212.
10. German, R. R., Armstrong, G. and Birkhead, G. S. (2001). Surveillance coordination group: updated guidelines for evaluating public health surveillance systems. Morbidity and Mortality Weekly Report, 50, 1-35.
11. Glick, I. D., Murray, S. R., Vasudevan, P., Marder, S. R. and Hu, R. J. (2001). Treatment with atypical antipsychotics: new indications and new populations. Journal of Psychiatric Research, 35, 187-191. (Pubitemid 32666214)
12. Goldman, J. G. (2011). New thoughts on thought disorders in Parkinson's disease: review of current research strategies and challenges. Parkinson's Disease, 2011. doi:10.4061/2011/675630.
13. Harding, A. J., Broe, G. A. and Halliday, G. M. (2002). Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain, 125, 391-403. (Pubitemid 34127441)
14. Jeste, D. V. et al. (2008). ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology, 33, 957-970. (Pubitemid 351367549)
15. Kales, H. C. et al. (2007). Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. American Journal of Psychiatry, 164, 1568-1576. (Pubitemid 350069737)
16. Kales, H. C. et al. (2011). Trends in antipsychotic use in dementia 1999-2007. Archives of General Psychiatry, 68, 190-197.
17. Liperoti, R., Pedone, C. and Corsonello, A. (2008). Antipsychotics for the treatment of behavioral and psychological symptoms of dementia (BPSD). Current Neuropharmacology, 6, 117-124. (Pubitemid 352024796)
18. López-Pousa, S. et al. (2006). Propuesta para un registro clínico de demencias. Revista de Neurología, 43, 32-38.
19. Mendez, M. F., Perryman, K. M., Miller, B. L. and Cummings, J. L. (1998). Behavioral differences between frontotemporal dementia and Alzheimer's disease: a comparison on the BEHAVE-AD rating scale. International Psychogeriatrics, 10, 155-162. (Pubitemid 28375546)
20. Morris, J. C. (1993). The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology, 43, 2412-2414. (Pubitemid 23346995)
21. Radley, D. C., Finkelstein, S. N. and Stafford, R. S. (2006). Off-label prescribing among office-based physiticians. Archives of Internal Medicine, 166, 1021-1026.
22. Ropacki, S. A. and Jeste, D. V. (2005). Epidemiology and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. American Journal of Psychiatry, 162, 2022-2030. (Pubitemid 41598255)
23. Schneider, L. S., Dagerman, K. S. and Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA, 294, 1934-1943. (Pubitemid 41464695)
24. Shapiro, S. S. and Wilk, M. B. (1965). An analysis of variance test for normality (complete samples). Biometrika, 52, 591-611.
25. Sink, K. M., Holden, K. F. and Yaffe, K. (2005). Pharmacological treatment of neuropsychiatric symptoms of dementia. JAMA, 293, 596-608. (Pubitemid 40171242)
26. Thi Phung, T. K., Waltoft, B. L., Kessing, L. V., Mortensen, P. B. and Waldemar, G. (2010). Time trend in diagnosing dementia in secondary care. Dementia and Geriatric Cognitive Disorders, 29, 146-153.
27. Tjia, J. et al. (2010). Daily medication use in nursing home residents with advanced dementia. Journal of the American Geriatrics Society, 58, 880-888.
28. Vilalta-Franch, J., López-Pousa, S., Garre-Olmo, J., Turón-Estrada, A. and Pericot-Nierga, I. (2008). Mortalidad en pacientes con enfermedad de Alzheimer tratados con neurolépticos atípicos. Revista de Neurología, 46, 129-134. (Pubitemid 351397735)
29. Weintraub, D., Chen, P., Ignacio, R. V., Mamikonyan, E. and Kales, H. C. (2011). Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Archives of Neurology, 68, 899-904.
30. Woods, S. W. et al. (2010). Incidence of tardive dyskinesia with atypical and conventional antipsychotic medications: prospective cohort study. Journal of Clinical Psychiatry, 71, 463-474.
31. Zahodne, L. B. and Fernandez, H. H. (2008). A review of the pathophysiology and treatment of psychosis in Parkinson disease. Drugs & Aging, 25, 665-682.